Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Merck KGaA’s $1.3 billion bid for Silence Therapeutics signals a high‑stakes push into RNA drug platforms.
Evidence dossier
Intelligence passport
Measured timeline
Coverage (5)
-
Merck KGaA to Buy Silence Therapeutics for $1.1 BillionBloomberg · 11h ago
-
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer winFierce Biotech · 11h ago
-
-
Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug dealReuters · 11h ago
-
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, GermanyBusiness Wire · 11h ago
Where it stands
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Merck KGaA’s $1.3 billion bid for Silence Therapeutics signals a high‑stakes push into RNA drug platforms.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Fierce Biotech emphasized that the acquisition follows a phase‑2 trial win for Silence’s siRNA drug targeting blood cancer. Barron’s noted the purchase price exceeds double the company’s prior valuation and highlighted a 125 % surge in its share price after the announcement.
The combined reporting underscores Merck’s strategic push into RNA therapeutics and reflects a premium valuation for the gene‑silencing platform. Discrepancies between the $1.1 billion and $1.3 billion amounts illustrate that final terms are not fully disclosed.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (50% supported) Updated 1h ago.
Answered
What is the reported value of Merck KGaA’s acquisition of Silence Therapeutics?
Sources cite values ranging from $1.1 billion (Bloomberg) to $1.3 billion (Reuters, Business Wire).
Which drug development milestone is linked to the deal?
Silence’s siRNA therapy achieved a phase‑2 trial win in blood cancer, as noted by Fierce Biotech.
When was the acquisition announced?
The announcement occurred on Oct 19 2026.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
AI Agent Company Decagon Held Early M&A Talks With ServiceNow, Others
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Bumble shares soar after report dating firm in $1bn takeover talks
Bumble shares surge 57% after reported $1.3 billion private deal.
Why I Am Buying REITs Hand Over Fist
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
KKR Strikes Deal to Buy Private-Capital Fund Administrator Gen II
KKR's $5.1 billion acquisition of Gen II marks a swift expansion into private‑capital fund administration.
Paramount Deal Delay Fuels Fears of Costly $52 Billion M&A Debt
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Cindy Holland Leaving Paramount Ahead Of WBD Merger
Paramount's streaming chief exits ahead of Warner Bros. Discovery merger.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.